Latest News & Features
Americas
The US Appeals Court for the Federal Circuit has affirmed a lower court decision that GlaxoSmithKline’s patent covering Avodart and Jalyn is valid, rejecting claims put forward by a group of generic drug makers. 28 February 2014
Asia
While Western pharmaceutical companies struggle to enforce their IP rights in India, Roche has taken an unorthodox but surprisingly effective stance, as Debashish Banerjee and Shukadev Khuraijam explain. 28 February 2014
Europe
A new referral to the CJEU should shed light on the extent of the so-called Bolar exemption in Europe, says Bernd Allekotte. 28 February 2014
Americas
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies. 28 February 2014
Europe
Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England. 28 February 2014
Asia
Bayer has announced that it plans to acquire Dihon Pharmaceutical Group, a Chinese company that makes over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products. 27 February 2014
Americas
The US District Court for the District of Maryland has ruled that Taiwanese company TWi Pharmaceuticals’ generic version of Par Pharmaceuticals’ Megace ES drug does not infringe US patent 7,101,576. 25 February 2014
Americas
Bayer will acquire Norwegian pharmaceutical company Algeta for €2.1 billion ($2.9 million), it announced on Monday. 24 February 2014
Americas
Actavis has announced another expansion with the $25 billion acquisition of US pharmaceutical company Forest Laboratories. 21 February 2014
Genetics
An individual gene profile provides a window into a person’s medical future, by examining DNA samples, but what are the best ways of regulating this developing technology? LSIPR looks at the challenges and possible solutions. 19 February 2014